Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | The movement towards targetted therapies in CLL

Thomas Kipps • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, describes the movement towards targetted therapies in chronic lymphocytic leukemia (CLL) treatment through better understanding the disease biology. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Thomas Kipps

1:28
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps • 11 Dec 2023
1:35
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Thomas Kipps • 11 Dec 2023
1:18
The use of genomics to help select treatment in CLL
Thomas Kipps • 9 Jun 2023
2:12
Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLL
Thomas Kipps • 9 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals